Abstract
Human immunodeficiency virus (HIV-1) envelope glycoproteins (Envs) are a main focus of immunogen design and vaccine development. Broadly neutralizing antibodies (bnAbs) against HIV-1 Envs target conserved epitopes and neutralize multiple HIV-1 viral strains. Nevertheless, application of bnAbs to therapy and prevention is limited by resistant strains that are developed or preexist within the viral population. Here we studied the HIV-1NAB9 Envs that were isolated from a person who injects drugs and exhibits high and broad resistance to multiple bnAbs. We identified an insertion of 11 amino acids in the V1 loop that allosterically modulates HIV-1NAB9 sensitivity to the PGT145 bnAb, which targets the Env trimer association domain and supports high level viral infectivity. Our data provide new insights into the mechanisms of HIV-1 resistance to bnAbs and into allosteric connectivity between different HIV-1 Env domains.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1558-1568 |
| Number of pages | 11 |
| Journal | ACS Infectious Diseases |
| Volume | 7 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 11 2021 |
Bibliographical note
Funding Information:We thank Peter Rusert and Alexandra Trkola from the Institute of Medical Virology, University of Zurich, for providing the HIV-1 Env-expression plasmid. We also thank the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH for providing the following anti-HIV-1 Env antibodies: PGT145, PG9, PGT128, and the psPAX2 plasmid. This work was supported by NIH/NIDA grant 1DP2DA049279-01 to A.H. Molecular graphics and analyses performed with UCSF Chimera, which is supported by NIH P41-GM103311. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NAB9
Publisher Copyright:
©
Keywords
- HIV-1
- broadly neutralizing antibodies
- entry inhibition
- envelope glycoproteins
